NCT06424834 Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries
| NCT ID | NCT06424834 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Stanford University |
| Condition | Angina Pectoris |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-10-10 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 150 participants in total. It began in 2024-10-10 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing. Participants will be treated with either medications that target the underlying cause of their chest pain or placebo for 4 weeks after a drug titration phase of 1-3 weeks. They will be asked to complete a series of questionnaires to evaluate their quality of life at the beginning and end of the study.
Eligibility Criteria
Inclusion Criteria: * All patients with stable angina referred to the Stanford University Hospital cardiac catheterization laboratory for clinically indicated coronary function testing are eligible for inclusion into the study. Specific inclusion criteria for randomization: * Absence of significant epicardial coronary artery disease on angiography * Fractional flow reserve \> 0.80 And ≥ 1 of the following: * Epicardial coronary spasm on acetylcholine testing * Microvascular spasm on acetylcholine testing * Coronary flow reserve \< 2.5 * Index of microcirculatory resistance ≥ 25 * Myocardial bridge on intravascular ultrasound with dobutamine resting full-cycle ratio ≤ 0.76 Exclusion Criteria: * Acute coronary syndrome less than one week prior to enrolment * Cardiomyopathy * Contraindications to beta-blockers or calcium channel blockers * Baseline systolic blood pressure \< 95 mmHg * Baseline heart rate \< 55 bpm
Contact & Investigator
Jennifer Tremmel, MD
PRINCIPAL INVESTIGATOR
Stanford University
Frequently Asked Questions
Who can join the NCT06424834 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Angina Pectoris. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06424834 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06424834 currently recruiting?
Yes, NCT06424834 is actively recruiting participants. Contact the research team at ccywong@stanford.edu for enrollment information.
Where is the NCT06424834 trial being conducted?
This trial is being conducted at Palo Alto, United States.
Who is sponsoring the NCT06424834 clinical trial?
NCT06424834 is sponsored by Stanford University. The principal investigator is Jennifer Tremmel, MD at Stanford University. The trial plans to enroll 150 participants.